Arboreal Bioinnovations has raised Rs 230 crore in a Series A funding round co-led by EAAA, the alternatives investment arm of Edelweiss, and agri-focused VC firm Omnivore, to scale its next-generation food ingredient and nutraceutical technology platform. The Lucknow-based startup builds specialty ingredients and supply chain solutions for food, beverage and nutraceutical brands, making it one of the largest Series A raises in India’s specialty ingredients sector.
Founded in May 2018 by Swati Pandey and Manish Chauhan, Arboreal Bioinnovations develops next-generation proteins, sugar reduction solutions, cocoa ingredients and nutraceutical actives. The round, announced on July 30, 2026, also saw participation from existing investor Rainmatter by Zerodha. Arboreal will use the fresh capital to expand manufacturing capacity, deepen R&D, and accelerate commercialisation of its ingredient technology across food and nutraceutical categories.
Why Did Arboreal Bioinnovations Raise a Rs 230 Crore Series A?
Arboreal Bioinnovations raised this Series A funding to address a structural gap in India’s food ingredient supply chain, where brands have historically relied on imported specialty ingredients for functional foods, low-sugar formulations and plant-based proteins. By co-leading the round, EAAA and Omnivore are betting that domestic ingredient manufacturing can capture demand that is currently met by global suppliers. The Rs 230 crore raise gives Arboreal capital to scale its Lucknow manufacturing base and invest in proprietary ingredient science.
What Does This Mean for India’s Food and Nutraceutical Brands?
For India’s fast-growing functional food and nutraceutical sector, a well-capitalised domestic ingredient supplier like Arboreal Bioinnovations could shorten supply chains and reduce dependence on imports for actives used in sugar reduction, next-gen proteins and cocoa-based formulations. Brands building better-for-you snacks, protein products and nutraceutical lines increasingly need ingredient partners who can scale manufacturing quickly, and Arboreal’s expanded capacity is positioned to serve that demand directly from India.
Industry Reaction and Expert Commentary
Investors framed the round as a bet on India’s ingredient manufacturing capability rather than just another consumer-facing food brand. EAAA and Omnivore’s decision to co-lead signals growing institutional confidence in B2B ingredient technology platforms, a category that has drawn less venture attention in India than direct-to-consumer food startups. Existing backer Rainmatter by Zerodha’s continued participation also points to investor conviction in Arboreal’s execution since its 2018 founding.
What Happens Next?
Arboreal Bioinnovations is expected to direct the Rs 230 crore toward expanding manufacturing capacity at its Lucknow base, scaling R&D for next-generation proteins and sugar reduction technology, and accelerating commercial rollout of its ingredient portfolio to food, beverage and nutraceutical brands. Watch for capacity expansion announcements and new brand partnerships as the company deploys this Series A capital over the coming quarters.
Frequently Asked Questions
What does Arboreal Bioinnovations do?
Arboreal Bioinnovations is a Lucknow-based specialty ingredient technology company that develops next-generation proteins, sugar reduction solutions, cocoa ingredients and nutraceutical actives for food, beverage and nutraceutical brands.
Who led Arboreal Bioinnovations’ Series A round?
The Rs 230 crore Series A was co-led by EAAA, the alternatives arm of Edelweiss, and agri-tech focused VC firm Omnivore, with participation from existing investor Rainmatter by Zerodha.
How will Arboreal use the new funding?
The company plans to expand its manufacturing capacity, strengthen research and development capabilities, and accelerate commercialisation of its next-generation ingredient technology across India.
Leave a comment